PAPP-A and IGFBP-4 fragment levels in patients with ST-elevation myocardial infarction treated with heparin and PCI.

Abstract

OBJECTIVES:

Circulating levels of pregnancy-associated plasma protein-A (PAPP-A) predict outcome in patients with acute coronary syndrome (ACS). Unfortunately, administration of heparin to patients with ACS increases circulating PAPP-A, probably by a detachment of PAPP-A from cell surfaces, inducing a considerable bias when using PAPP-A as a biomarker. It remains unknown whether PAPP-A-derived N- and C-terminal fragments of insulin-like growth factor binding protein-4 (NT-IGFBP-4/CT-IGFBP-4) are acutely affected by the increase in PAPP-A.

METHODS:

We prospectively included 78 patients with ST-segment elevation myocardial infarction (STEMI) treated with percutaneous coronary intervention (PCI). Prior to PCI, patients were injected with 10,000IU of unfractionated heparin (UFH). Blood samples were collected immediately before PCI, but after UFH-injection, immediately after PCI and on day 1 and day 2. Plasma IGFBP-4, CT-IGFBP-4 and NT-IGFBP-4 levels were determined by specific, novel immunoassays, and PAPP-A and IGF-I by commercial immunoassays.

RESULTS:

Plasma PAPP-A was strongly elevated upon STEMI, UFH-administration and PCI with mean concentrations (95%-confidence interval) pre-PCI, post-PCI, day 1, and day 2 of 13.0 (11.2;15.2), 14.8 (13.1;16.8), 1.03 (0.90;1.18), and 1.08 (0.92;1.28) μg/L, respectively (p<0.0001). Pre-PCI concentrations of IGFBP-4, CT-IGFBP-4 and NT-IGFBP-4 were 154 (142;166), 53 (47;60) and 136 (122;150) μg/L, and levels were unaltered post-PCI. Concentrations increased on day 1 by 63 (43;87)%, 69 (36;110)%, and 47 (21;79)%, respectively (p<0.0001), i.e. at a time point when PAPP-A levels had normalized.

CONCLUSION:

Plasma IGFBP-4-fragment levels are not acutely altered in patients with STEMI treated with UFH and PCI. Thus, they possess potentials as prognostic markers in ACS patients.

• Authors: Rikke Hjortebjerg, Søren Lindberg, Søren Hoffmann, Jan S Jensen, Claus Oxvig, Mette Bjerre, Jan Frystyk
• Journal: Clinical biochemistry (Clin Biochem) Vol. 48 Issue 4-5 Pg. 322-8 (Mar 2015) ISSN: 1873-2933 [Electronic] United States
• PMID: 25489725 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2014 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Chemical References

• Anticoagulants
• Biomarkers
• Insulin-Like Growth Factor Binding Protein 4
• Heparin
• Pregnancy-Associated Plasma Protein-A
• PAPPA protein, human

Topics

• Aged
• Anticoagulants (therapeutic use)
• Biomarkers (blood)
• Female
• Heparin (therapeutic use)
• Humans
• Insulin-Like Growth Factor Binding Protein 4 (blood)
• Male
• Middle Aged
• Myocardial Infarction (blood, diagnosis, therapy)
• Percutaneous Coronary Intervention (trends)
• Pregnancy-Associated Plasma Protein-A (metabolism)
• Prospective Studies
• Treatment Outcome